Antiretroviral

DRUG3 trials

Sponsors

ANRS, Emerging Infectious Diseases, MRC/UVRI and LSHTM Uganda Research Unit

Conditions

HIV-1-infectionHIV-2 Infection

Phase 3

Reducing Antiretroviral Treatments

TerminatedNCT04051970

ANRS, Emerging Infectious DiseasesHIV-1-infection

Start: 2019-11-27End: 2022-12-14Updated: 2026-06-08

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

Active, not recruitingNCT05546242

MRC/UVRI and LSHTM Uganda Research UnitHIV-1-infection

Start: 2022-12-08End: 2026-03-31Updated: 2024-09-27

Unknown Phase

Cohorte Nationale VIH-2

ANRS, Emerging Infectious DiseasesHIV-2 Infection

Start: 1994-01-01End: 2022-09-30Target: 1185Updated: 2020-12-08

Related Papers

Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

2025-03-28